Sun Pharma posts 30pc rise in Q4 profit

BENGALURU, May 28 (Reuters): Sun Pharmaceuti-cal Industries Ltd, India's largest drugmaker by revenue, reported a 29.6 per cent rise in fourth-quarter profit, as it benefited from lower expenses and higher sales of specialty drugs.
The company's consolidated profit before exceptional items and tax rose to 24.11 billion rupees ($291.7 million) for the quarter ended March 31, it said in an exchange filing.
Total revenue from operations climbed 15.7 per cent to 109.31 billion rupees, while input costs declined 13.2 per cent.
The company, founded in 1983, makes over-the-counter medications, anti-retrovirals and active pharmaceutical ingredients for chronic and acute treatments.
Drug sales in India, which account for over 31 per cent of Sun Pharma's total consolidated sales, rose 8.7 per cent year-on-year.